Biotech company is testing oral medication in Phase 3 clinical trials
Biotechnology company Alzheon Inc. has raised $50 million in new venture capital to complete clinical trials of a potential oral medication for Alzheimer’s disease.
Framingham, Mass.-based Alzheon is testing the drug in late-stage, Phase 3 clinical trials. The company, which plans to complete enrollment of the 300-person study this year, expects to have data from the trial in 2024, Chief Executive Martin Tolar said.
If the study is successful, Alzheon also expects to seek Food and Drug Administration approval that year, Dr. Tolar said.
Read the full article here